Biotech Values

[caravon]

what exactly are they spending $33 million/year on, when they have no company-sponsored trials to run

Well, quite many biotech are exclusively in business of transferring shareholder equities into these companies Sr. management pockets. The rest for them is very much secondary. Unfortunately, it is a reality.

As for SEC, its people are too busy watching Internet porn.